+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review

Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review

Bmc Geriatrics 15: 31

The cumulative effect of taking multiple medicines with anticholinergic properties termed as anticholinergic burden can adversely impact cognition, physical function and increase the risk of mortality. Expert opinion derived risk scales are routinely used in research and clinical practice to quantify anticholinergic burden. These scales rank the anticholinergic activity of medicines into four categories, ranging from no anticholinergic activity (= 0) to definite/high anticholinergic activity (= 3). The aim of this systematic review was to compare anticholinergic burden quantified by the anticholinergic risk scales and evaluate associations with adverse outcomes in older people. We conducted a literature search in Ovid MEDLINE, EMBASE and PsycINFO from 1984-2014 to identify expert opinion derived anticholinergic risk scales. In addition to this, a citation analysis was performed in Web of Science and Google Scholar to track prospective citing of references of selected articles for assessment of individual scales for adverse anticholinergic outcomes. The primary outcomes of interest were functional and cognitive outcomes associated with anticholinergic burden in older people. The critical appraisals of the included studies were performed by two independent reviewers and the data were extracted onto standardised forms. The primary electronic literature search identified a total of 1250 records in the 3 different databases. On the basis of full-text analysis, we identified 7 expert-based anticholinergic rating scales that met the inclusion criteria. The rating of anticholinergic activity for medicines among these rating scales was inconsistent. For example, quetiapine was rated as having high anticholinergic activity in one scale (n = 1), moderate in another scale (n = 1) and low in two other scales (n = 2). Citation analysis of the individual scales showed that the Anticholinergic Cognitive Burden (ACB) scale was the most frequently validated expert based anticholinergic scale for adverse outcomes (N = 13). In conclusion, there is not one standardised tool for measuring anticholinergic burden. Cohort studies have shown that higher anticholinergic burden is associated with negative brain effects, poorer cognitive and functional outcomes.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057211055

Download citation: RISBibTeXText

PMID: 25879993

DOI: 10.1186/s12877-015-0029-9

Related references

Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. Journal of the American Geriatrics Society 63(1): 85-90, 2015

Anticholinergic Drug Burden Tools/Scales and Adverse Outcomes in Different Clinical Settings: A Systematic Review of Reviews. Drugs and Aging 2018, 2018

A systematic review and meta-analysis on serum anticholinergic activity and adverse outcomes in older people. Research in Social and Administrative Pharmacy 12(5): E35-E36, 2016

Serum Anticholinergic Activity and Cognitive and Functional Adverse Outcomes in Older People: A Systematic Review and Meta-Analysis of the Literature. Plos One 11(3): E0151084, 2016

Anticholinergic component of the Drug Burden Index and the Anticholinergic Drug Scale as measures of anticholinergic exposure in older people in New Zealand: a population-level study. Drugs and Aging 30(11): 927-934, 2014

Systematic review of anticholinergic risk scales in older adults. European Journal of Clinical Pharmacology 69(7): 1485-1496, 2013

Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. American Journal of Geriatric PharmacoTherapy 4(1): 42-51, 2006

Impact of anticholinergic discontinuation on cognitive outcomes in older people: a systematic review. Drugs and Aging 31(3): 185-192, 2014

The anticholinergic risk scale and anticholinergic adverse effects in older persons. Archives of Internal Medicine 168(5): 508-513, 2008

Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study. Drugs and Aging 30(5): 321-330, 2013

Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs and Aging 30(2): 103-112, 2013

Association of anticholinergic burden with adverse effects in older people with intellectual disabilities: an observational cross-sectional study. British Journal of Psychiatry 209(6): 504-510, 2016

Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale. Drugs & Aging 30(2): 103-112, 2013

Anticholinergic Burden and Most Common Anticholinergic-acting Medicines in Older General Practice Patients. Zdravstveno Varstvo 57(3): 140-147, 2018

Prevalence, risk factors and adverse outcomes of anticholinergic burden in patients with advanced chronic conditions at hospital admission. Geriatrics and Gerontology International 18(8): 1159-1165, 2018